<DOC>
	<DOC>NCT01738191</DOC>
	<brief_summary>The purpose of this study is to determine the safety and effectiveness of a drug called atomoxetine for the treatment of cognitive impairment for Parkinson 's disease. Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit. It works to increase the amount of norepinephrine (a chemical in the brain that helps keep us awake and alert) in our brain. ATM has not been approved by the Food and Drug Administration (FDA) to be used in the treatment of PD.</brief_summary>
	<brief_title>Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Confirmed diagnosis of idiopathic PD according to the United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) criteria Male or female subjects aged between 35 and 75 years, inclusive at the time of consent Hoehn &amp; Yahr Stage IIV Diagnosis of PD mild cognitive impairment (MCI), Montreal Cognitive Assessment (MoCa) score 2125 Stable concomitant medications for 60 days Secondary parkinsonism or atypical parkinsonism, Prior Deep Brain Stimulation (DBS) or other brain surgery PD Dementia; MoCA score &lt;21 Presence of Psychosis, pregnancy, suicidal ideation on the Columbia Suicide Severity Rating Scale (CSSRS) type 4 or 5 in past 3 months. Current treatment with anticholinergics, monoamine oxidase (MAO) inhibitors or neuroleptics (including quetiapine) Serious cardiac abnormalities, Narrow angle glaucoma, Pheochromocytoma, Bipolar Disorder Liver Function Tests (LFTs) &gt;1.5 X upper limit of normal value</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Parkinson's disease</keyword>
</DOC>